The AVEO Oncology management team comprises executives with years of oncology and pharmaceutical industry experience and expertise, and a proven track record for success in bringing important new therapies to patients.
President and CEO
Michael P. Bailey serves as president and chief executive officer of AVEO and a member of the company’s board of directors, bringing more than 20 years of experience in the pharmaceutical industry to the company. He joined AVEO in 2010 as the company’s chief commercial officer, was named chief business officer in 2013 and assumed his current roles in January 2015. Mr. Bailey joined AVEO from Synta Pharmaceuticals, where he served as senior vice president, business development, and chief commercial officer since 2008. Prior to joining Synta, Mr. Bailey led ImClone Systems’ (now Eli Lilly) Worldwide Commercial Organization. During his nine year tenure at ImClone, he was responsible for commercial aspects of the planning and launch of ERBITUX® (cetuximab) across multiple oncology indications, as well as new product planning for the ImClone development portfolio, which included CYRAMZA® (ramucirumab) and necitumumab. In addition, Mr. Bailey was a key member of the strategic leadership committees for ImClone and its North American and worldwide partnerships. Prior to joining ImClone, Mr. Bailey managed the cardiovascular development portfolio at Genentech, Inc., and was a key member of their global commercial partnership teams. Mr. Bailey started his career in the pharmaceutical industry as part of SmithKline Beecham’s Executive Marketing Development Program, where he held a variety of commercial roles, including sales, strategic planning, and product management. Mr. Bailey received a B.S. in psychology from St. Lawrence University and an M.B.A. in international marketing from the Mendoza College of Business at University of Notre Dame.
Senior Vice President of Technical Operations and Quality Assurance
Emile Farhan has more than 20 years of experience in the pharmaceutical industry. As the Vice President of Technical Operations, he leads all aspects of chemistry, manufacturing and control of AVEO programs. He joined AVEO in April 2012 after his tenure at Eisai, where he served as the Head of CMC Global Operations Coordination for the US and Europe and as the Director of Pharmaceutical Development at MGI prior to its acquisition by Eisai. Prior to MGI, he served as the Senior Director of Product Development and Manufacturing at Mersana Therapeutics. Dr. Farhan also held several leadership roles at Pharm-Eco from 1992 until its acquisition by Johnson Matthey in 2000 and at Johnson Matthey Pharma from 2000 to 2006, where he was the Senior Director of Technical Operations and Scientific Affairs. Dr. Farhan holds a Ph.D. from Brandeis University and an MS from the University of Massachusetts.
Senior Vice President, Business Analytics and Commercial Operations
Mike Ferraresso currently serves as AVEO’s Senior Vice President, Business Analytics and Commercial Operations. Prior to joining AVEO, he served as Vice President, Commercial Operations at Verastem, Mr. Ferraresso also previously served as Vice President, Commercial at Infinity Pharmaceuticals where he was instrumental in designing the commercial strategy for duvelisib and chaired the joint commercial committee for the partnership. From 1998-2013, he served in sales and commercial operations roles of increasing responsibility at several biotechnology and pharmaceutical companies, including at AVEO, AMAG Pharmaceuticals, Critical Therapeutics, Praecis Pharmaceuticals, Ascent Pediatrics and Muro Pharmaceuticals. Mr. Ferraresso has extensive experience in commercial strategy including partnerships, development, pricing and field deployment models and has launched Oprapred™, Plenaxis™, Zyflo™ and Feraheme™. Mr. Ferraresso holds a BA degree in Economics from Assumption College.
Chief Financial Officer
Erick Lucera brings to AVEO over twenty years of financial, operational, and investment experience in the biotechnology and medical device industries. He most recently served as chief financial officer of Valeritas, a publicly traded commercial-stage medical technology company focused on developing solutions for people with diabetes, where he led the company through multiple successful public offerings. Prior to Valeritas, Mr. Lucera served as the chief financial officer, treasurer, and secretary of Viventia Bio (acquired by Eleven Biotherapeutics, Inc., now Sesen Bio), a biotechnology company focused on developing targeted protein therapeutics for the treatment of cancer. He also previously served as vice president, corporate development at Aratana Therapeutics, a veterinary biopharmaceutical company, where he helped grow the company’s product pipeline through a series of acquisitions and in-licensing transactions financed through five public and private offerings of nearly $250 million. Previously, Mr. Lucera was vice president, corporate development at Sunshine Heart (now CHF Solution), a medical device manufacturer.
Prior to Sunshine Heart, Mr. Lucera spent over 15 years in investment management as a healthcare analyst at Eaton Vance, the portfolio manager of the Triathlon Life Sciences Fund at Intrepid Capital, and as head of the healthcare research team at Independence Investments. He began his career as a staff auditor and accountant at Price Waterhouse & Co. (now PwC). Mr. Lucera holds a CPH from Harvard University, an MS from Boston College, an MBA from Indiana University Bloomington, and a BS in accounting from the University of Delaware. Mr. Lucera currently holds a CFA designation. Mr. Lucera previously held CMA and CPA designations, which are expired.
Chief Medical Officer
Michael N. Needle, M.D., serves as chief medical officer of AVEO, and brings more than 15 years of pharmaceutical industry experience in drug development and regulatory affairs. This includes central roles in the development of oncology and hematology drugs, including Erbitux® (cetuximab), Revlimid® (lenalidomide) and Pomalyst® (Pomalidomide). He most recently served as the Chief Medical Officer of Array BioPharma. Prior to Array, Dr. Needle was Chief Medical Officer of the Multiple Myeloma Research Foundation and Consortium (MMRF). Prior to MMRF, he held multiple Vice President level positions at Celgene in Clinical Research and Development in Oncology, Strategic Medical Business Development, and Pediatric Strategy. Dr. Needle also served as the Vice President of Clinical Affairs at ImClone Systems Incorporated. Dr. Needle did his fellowship in Pediatric Hematology / Oncology at the Children’s Hospital Medical Center and the Fred Hutchinson Cancer Research Center of the University of Washington in Seattle and the University of Texas M.D. Anderson Cancer Center in Houston. Dr. Needle has held faculty positions at the University of Pennsylvania and Columbia University. Dr. Needle graduated from Binghamton University with a Bachelor of Arts in Physics and received his medical degree from SUNY Downstate Medical Center, in Brooklyn, New York.
Senior Vice President and General Counsel
Karuna Rubin serves as Senior Vice President and General Counsel of AVEO. Prior to AVEO, Ms. Rubin served as an Associate at Arnold & Porter, LLP and as Assistant General Counsel at Cenveo, Inc. She has extensive experience representing public companies in a variety of industries in securities, finance, mergers and acquisitions, litigation and other matters. Ms. Rubin received her A.B. in International Relations from Brown University and her J.D. from Columbia Law School.
Vice President, Financial Accounting and Reporting
Lisa Bruneau brings to AVEO more than 20 years of financial and public company experience in the life sciences industry. She joined AVEO in 2016 as the Vice President of Financial Accounting and Reporting and Treasurer. Ms. Bruneau joined AVEO from Synta Pharmaceuticals, where she served as Senior Director of Finance and Director of Finance since 2004, including the company’s initial public offering. Prior to Synta, Ms. Bruneau worked at Diomed and Acambis (formerly OraVax) where she held various positions of increasing responsibility in finance and accounting, including OraVax’s initial public offering. Ms. Bruneau holds a B.S. in Business, Accounting and Finance from Bridgewater State College and an M.B.A. in International Business from Suffolk University in Boston.
Vice President, Clinical Operations
Valerie Legagneur brings 20+ years of clinical research experience to her role as AVEO’s Vice President of Clinical Operations. Prior to joining AVEO’s management team, Ms. Legagneur led up the Clinical Operations group as Vice President, Clinical Operations at Odonate Therapeutics Inc. Ms. Legagneur also worked at Pfizer Inc. for 10+ years in various roles of increasing responsibility within Development Operations. In her last role at Pfizer she served as the Director, Clinical Operations Program Lead for the Hematology / Oncology Portfolio. During her time at Pfizer she led several Clinical Operations teams that supported the clinical trial executions leading to approvals for IBRANCE™ and BESPONSA™. Ms. Legagneur received both BA and MA degrees from State University of New York at Stony Brook.
Interim Head of Regulatory Affairs
Darlene Noci currently serves as AVEO’s Interim Head of Regulatory Affairs. Ms. Noci brings to AVEO over 20 years of leadership experience in global regulatory affairs and strategic drug development at several leading biotechnology and pharmaceutical companies. She has contributed to several successful drug approvals, including Fabrazyme®, Mozobil®, Clolar®/Evoltra®, and BAVENCIO®. Prior to founding her own regulatory consulting firm in 2018, she served as Vice President, Regulatory Affairs and Quality Assurance at X4 Pharmaceuticals. Prior to X4, she served as Global Regulatory Lead Strategist, Immuno-Oncology, at EMD Serono, the North America biopharma business of Merck KGaA, Darmstadt, Germany. In this position, she was the lead regulatory strategist for BAVENCIO®, the company’s anti-programmed death-ligand 1 (PD-L1) antibody, where she led the team responsible for securing its Breakthrough Therapy Designation, which subsequently led to the drug’s Accelerated Approval for the treatment of patients with Merkel cell carcinoma. Ms. Noci was also instrumental in the global clinical development plan of BAVENCIO® in various solid tumors, including urothelial carcinoma and renal cell carcinoma. Prior to EMD Serono, Ms. Noci served as an oncology and rare disease-focused regulatory lead at several companies, including Infinity Pharmaceuticals, Sanofi, and Genzyme. She received a Bachelor’s degree in Political Science from Adelphi University and a Master’s degree in Government from Harvard University.
Vice President of Market Access
Jason Noto brings over 20 years of commercial leadership experience to his role as Vice President of Market Access at AVEO Oncology. Prior to joining AVEO, Jason served as Vice President at 1798 Consultants, a strategic market access consultancy specializing in integrated channel strategy, payer contract development and assessment, financial impact analysis, and related Access functions. Earlier, Jason served as Senior Director of Market Access Strategy and Payer Marketing at Amag Pharmaceuticals, leading Access marketing efforts across all business units totaling >$600M in revenue in 2017.
Prior to his tenure at Amag Pharmaceuticals, Mr. Noto held various launch, inline, and multi-channel marketing leadership roles of increasing responsibility at Sunovion Pharmaceuticals, Alkermes, and Bristol-Myers Squibb Company. During his career, Mr. Noto has had responsibility for the US commercial launch of various specialty products in oncology, immunology, CNS, & ultra-orphan disease states. Mr. Noto received a B.S. in Business Administration from Le Moyne College and an M.B.A. in finance from the Carroll School of Management at Boston College.
Vice President, Marketing
Kevin Peacock currently serves as AVEO’s Vice President of Marketing. Prior to joining AVEO, he served as both the Vice President, New Product Planning and Business Development at Lycera where he was leading the early commercialization process for Lycera’s novel immune-oncology compounds and in 2015 completed an exclusive strategic collaboration and license with Celgene resulting in $100M in non-dilutive financing. Mr. Peacock also previously served as Vice President, Global Marketing and Business Analytics at Dendreon, where he led the launch of Provenge® in select European countries and managed the US Business Analytics team. Mr. Peacock was Senior Director and Product Champion for Savient Pharmaceuticals while working on Krystexxa® and previously served as Senior Director of New Product Planning at Allos Therapeutics. Prior to that, Mr. Peacock held various roles on the ERBITUX® brand team while at ImClone Systems. Mr. Peacock’s has extensive experience in the oncology commercialization process including marketing, market research, new product planning and product development on the R&D side. Mr. Peacock earned his Bachelor of Administration in Finance and Risk Management from Temple University.
Vice President, Medical Affairs
Dan brings 20 years of clinical, academic, biopharmaceutical, and military medicine experience as a physician and scientist. His background includes clinical roles in private practice and Hospice and Palliative Care, faculty appointments at Yale and Tufts University, and as a battalion surgeon for a US Marine infantry unit. As a leader in Medical Affairs, Dan has led the launch of multiple, first oncology products in the US. He brings broad medical affairs experience with specific expertise in clinical strategy development, IST and Phase IV study design, KOL engagement, publication strategy, and building productive, cross-functional teams. Most importantly, Dan loves working with people who are passionate about collaboration and innovative thinking as a path to delivering excellence in their mission to serve patients.